Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 12/20 | 0.81 |
| ▸ | CNR1 | P21554 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7216755 | 0.93 | CNR2 (0.81) | CNR2CNR1 | |
| SCHEMBL7224460 | 0.90 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL7216787 | 0.87 | CNR2 (0.81) | CNR2CNR1 | |
| SCHEMBL7216990 | 0.83 | CNR2 (0.61) | CNR2CNR1MEN1POLBKMT2A | |
| SCHEMBL7217492 | 0.83 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL7223450 | 0.83 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL7217490 | 0.83 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL7216928 | 0.82 | CNR2 (0.84) | CNR2CNR1 | |
| SCHEMBL7224182 | 0.82 | CNR2 (0.61) | CNR2CNR1 | |
| SCHEMBL7224699 | 0.82 | CNR2 (0.80) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1254115-A2 | CANNABINOID RECEPTOR MODULATORS, THEIR PROCESSES OF PREPARATION, AND USE OF CANNABINOID RECEPTOR MODULATORS FOR TREATING RESPIRATORY AND NON-RESPIRATORY DISEASES | Bristol-Myers Squibb Company (US) | 2002-11-06 | — | — | EP | claimed |
| US-20020119972-A1 | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases | BRISTOL-MYERS SQUIBB COMPANY | 2002-08-29 | — | — | US | claimed |
| WO-2001058869-A2 | CANNABINOID RECEPTOR MODULATORS, THEIR PROCESSES OF PREPARATION, AND USE OF CANNABINOID RECEPTOR MODULATORS IN TREATING RESPIRATORY AND NON-RESPIRATORY DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-08-16 | — | — | WO | claimed |
| US-6653304-B2 | Antiarthritic agents; skin disorders; anticarcinogenic agents | BRISTOL-MYERS SQUIBB CO. | 2003-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119972-A1 | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885MEN1 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.